Andrew D Krystal, MD, MS
University of California, San Francisco · Duke University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andrew D Krystal, MD, MS as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:18 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT05463861 · Lemborexant in Delayed Sleep Phase SyndromeStanford University · recruiting · Delayed Sleep Phase Syndrome · principal investigator
- Ph1NCT02218775 · FASTMAS (Fast-Fail Trials in Mood and Anxiety Spectrum Disorders) Kappa Opioid Receptor Phase 1 StudyAndrew Krystal · withdrawn · Anxiety Disorders · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:18 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 30 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Protocol Review & Monitoring CommitteeP30CA014236 · NCI · DUKE UNIVERSITY · fiscal years 2021 to 2026 · $223,070 awarded in 2026Same name and institution; not confirmed by an ID
- The Duke University - Duke Cancer Institute National Clinical Trials Network LAPS (UG1) Support GrantUG1CA233253 · NCI · DUKE UNIVERSITY · fiscal years 2026 · $634,423 awarded in 2026Same name and institution; not confirmed by an ID
- Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPCR01CA256157 · NCI · DUKE UNIVERSITY · fiscal years 2020 to 2025 · $647,291 awarded in 2025Same name and institution; not confirmed by an ID
- Function and evolution of strains in the gut microbiotaR15GM160989 · NIGMS · CALIFORNIA STATE UNIVERSITY SACRAMENTO · fiscal years 2025 · $532,500 awarded in 2025Same name and institution; not confirmed by an ID
- Targeting convergent oncogenic signaling during AR inhibition to overcome metastasis and immune evasion in prostate cancerR01CA233585 · NCI · DUKE UNIVERSITY · fiscal years 2019 to 2023 · $442,930 awarded in 2023Same name and institution; not confirmed by an ID
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.